# Repositioning of Alogliptin to Mitigate Secondary Injury Induced by Repetitive TBI: Potential Role of its Antioxidant and Anti- Inflammatory Effects

**Authors:** Hossam A. Raslan, Haidy E. Michel, Esther T. Menze, Amira A. El-Gazar

PMC · DOI: 10.1007/s11481-025-10271-w · Journal of Neuroimmune Pharmacology · 2026-01-13

## TL;DR

This study shows that alogliptin may help reduce brain damage from repeated injuries by reducing stress and inflammation in the brain.

## Contribution

The study reveals alogliptin's potential as a treatment for repetitive traumatic brain injury through its antioxidant and anti-inflammatory effects.

## Key findings

- Alogliptin improved motor function and reduced brain damage in rats with repetitive traumatic brain injury.
- Alogliptin suppressed ER stress markers like ATF6 and GRP78 and reduced β-amyloid and Tau protein aggregation.
- Alogliptin increased BDNF and TrKB levels and modulated miRNA-322 and miRNA-125b gene expression.

## Abstract

Repetitive traumatic brain injury (RTBI) refers to brain injuries resulting from an external mechanical force causing cumulative and frequently severe neurological consequences. This study aimed to explore the neuroprotective effect of alogliptin (ALO) on RTBI-provoked endoplasmic reticulum (ER) stress and investigate the potential underlying mechanisms. For RTBI induction, rats were exposed to a sharp-edged weight at the right interior frontal area of the right cortex, one drop per day for five successive days. ALO (20 mg/kg/day, p.o.) was administered for one week. Results depicted that ALO recovered motor abnormalities and enhanced motor coordination in the open field test, decreased immobility and increased climbing time in the forced swimming test, and corrected histological aberrations. Moreover, ALO counteracted RTBI-triggered ER stress via suppression of activating transcription factor 6 (ATF6), glucose-regulated protein 78 (GRP78), aggregation of β-amyloid and Tau proteins, as well as elevation of the cortical content of brain-derived neurotrophic factor (BDNF) and its receptor, tropomyosin receptor kinase B (TrKB). ALO also exhibited an antioxidant and anti-inflammatory potential in addition to its effect on the gene expression of miRNAs (miRNA-322 and miRNA-125b). In conclusion, ALO exhibited a neuroprotective effect by mitigating ER stress induced in an RTBI rat model.

The online version contains supplementary material available at 10.1007/s11481-025-10271-w.

## Linked entities

- **Genes:** ATF6 (activating transcription factor 6) [NCBI Gene 22926], HSPA5 (heat shock protein family A (Hsp70) member 5) [NCBI Gene 3309], BDNF (brain derived neurotrophic factor) [NCBI Gene 627], NTRK2 (neurotrophic receptor tyrosine kinase 2) [NCBI Gene 4915]
- **Proteins:** MAPT (microtubule associated protein tau)
- **Chemicals:** alogliptin (PubChem CID 11450633)
- **Diseases:** traumatic brain injury (MONDO:0858950)
- **Species:** Rattus norvegicus (taxon 10116)

## Full-text entities

- **Genes:** Hspa5 (heat shock protein family A (Hsp70) member 5) [NCBI Gene 25617] {aka BIP, GRP 78, GRP78}, Atf6 (activating transcription factor 6) [NCBI Gene 304962], Bdnf (brain-derived neurotrophic factor) [NCBI Gene 24225], Ntrk2 (neurotrophic receptor tyrosine kinase 2) [NCBI Gene 25054] {aka RATTRKB1, TRKB1, Tkrb, trk-B, trkB}
- **Diseases:** Injury (MESH:D014947), motor abnormalities (MESH:D000014), Inflammatory (MESH:D007249), brain injuries (MESH:D001930), RTBI (MESH:D000070642)
- **Chemicals:** ALO (MESH:C520853)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12799724/full.md

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12799724/full.md

## References

13 references — full list in the complete paper: https://tomesphere.com/paper/PMC12799724/full.md

---
Source: https://tomesphere.com/paper/PMC12799724